PledPharma Readies PledOx For Phase III FDA Talks And Partnering
This article was originally published in The Pink Sheet Daily
PledPharma unveiled potentially transforming Phase IIb top-line results for its new medicine PledOx, which aims to reduce severe side effects from chemotherapy. The Swedish small cap firm now will engage with regulators to map out its Phase III program – and woo potential commercial partners for the needed financing.
You may also be interested in...
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.
Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.